卵巣がん治療薬の世界市場レポート 2025年

卵巣がん治療薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR14.7％で100億7,000万米ドルに成長します。予測期間の成長は、高齢者人口の増加と医薬品研究開発費の増加に起因しています。予測期間における主な動向としては、抗体薬物複合体の上市、収益と製品提供を改善するための提携と共同研究、卵巣がんに対する移植型薬剤工場への注力などが挙げられます。

卵巣がんの有病率の増加は、卵巣がん治療薬市場の成長の主要な促進要因です。卵巣がんは、女性で8番目に多く診断されるがんであり、世界的には18番目に多いがんです。2023年に米国がん協会が報告した卵巣がん統計によると、米国だけで推定19,710人の新規がん罹患者と13,270人の関連死亡者が予想されています。この世界の卵巣がん罹患率の上昇は、卵巣がん治療薬市場の拡大に大きく寄与しています。

卵巣がんに対する政府の取り組みや資金援助は、今後卵巣がん治療薬市場の成長を大きく促進すると予想されます。これらのイニシアチブは、公共サービスや経済の強化を目的としたプロジェクトで選ばれた事業体に財政的支援を提供します。卵巣がん研究における政府の援助は、この病気の患者の生活の質と生存率を向上させる上で重要な役割を果たしています。例えば、2022年7月、米国の非営利団体である卵巣がん研究同盟（Ovarian Cancer Research Alliance, Inc.）は、ヨハンナの法と卵巣がん対策イニシアチブの両方に200万米ドルの追加配分を発表したが、これは22年度に承認された50万米ドル増額分からの大幅な増額です。その結果、卵巣がんに対する政府の取り組みと資金援助が卵巣がん治療薬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界卵巣がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の卵巣がん治療薬市場：成長率分析
• 世界の卵巣がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の卵巣がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界卵巣がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の卵巣がん治療薬市場腫瘍の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 上皮性卵巣がん
• 胚細胞卵巣がん
• 間質細胞卵巣がん
• 世界の卵巣がん治療薬市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルキル化剤
• 有糸分裂阻害剤
• VEGF/VEGFR阻害剤
• PARP阻害剤
• その他の薬物の種類
• 世界の卵巣がん治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• ドラッグストア
• その他の流通チャネル
• 世界の卵巣がん治療薬市場上皮性卵巣がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 漿液性がん
• 子宮内膜がん
• 明細胞がん
• 粘液がん
• 世界の卵巣がん治療薬市場、胚細胞卵巣がんの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 未分化胚細胞腫
• 卵黄嚢腫瘍
• 奇形腫
• 胎児性がん
• 世界の卵巣がん治療薬市場間質細胞卵巣がんの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 顆粒膜細胞腫瘍
• セルトリ・ライディッヒ細胞腫瘍
• テコマ
• 線維腫

第7章 地域別・国別分析

• 世界の卵巣がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の卵巣がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 卵巣がん治療薬市場：競合情勢
• 卵巣がん治療薬市場：企業プロファイル
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Clovis Oncology
• Pfizer, Inc.
• Novartis AG
• Pharma Mar SA
• Vivesto
• BDR Pharmaceutical
• GLS Pharma
• Eisai Co., Ltd.
• Denovo Biopharma
• Jiangsu Hengrui Medicine
• BeiGene
• Innovent Biologics
• Zai Lab
• EUSA Pharma
• Recordati

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 卵巣がん治療薬市場2029：新たな機会を提供する国
• 卵巣がん治療薬市場2029：新たな機会を提供するセグメント
• 卵巣がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ovarian cancer drugs are pharmaceuticals specifically designed for the treatment of ovarian cancer, a condition arising from abnormal cell growth in the ovaries. This sector encompasses establishments engaged in the production of drugs utilized in ovarian cancer treatment through chemotherapy, radiation, and surgery. Notable examples of ovarian cancer drugs include Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide), among others.

Ovarian cancer drugs target different types of tumors, namely epithelial ovarian cancer, germ cell ovarian cancer, and stromal cell ovarian cancer. Epithelial ovarian cancer is the most prevalent type, accounting for 90% of ovarian tumors. This form originates in the epithelial layer that covers the ovary. The diverse categories of drugs for ovarian cancer treatment include alkylating agents, mitotic inhibitors, VEGF/VEGF inhibitors, PARP inhibitors, among others. These drugs are distributed through various channels such as hospital pharmacies, drug stores, and others.

The ovarian cancer drugs market research report is one of a series of new reports from The Business Research Company that provides ovarian cancer drugs market statistics, including ovarian cancer drugs industry global market size, regional shares, competitors with an ovarian cancer drugs market share, detailed ovarian cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer drugs industry. This ovarian cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ovarian cancer drugs market size has grown rapidly in recent years. It will grow from $5.1 billion in 2024 to $5.82 billion in 2025 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to rising incidences of ovarian cancer, a rise of new medications and therapies, an increase in government initiatives for ovarian cancer treatment and increased healthcare expenditure.

The ovarian cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $10.07 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to increasing geriatric population and an increase in pharmaceutical R&D expenditure. Major trends in the forecast period include launching antibody-drug conjugates, partnerships and collaborations to improve revenues and product offerings, and focus on implanted drug factories for ovarian cancer.

The increasing prevalence of ovarian cancer is a key driver of growth in the ovarian cancer drugs market. Ovarian cancer ranks as the eighth most commonly diagnosed cancer in women and the 18th most prevalent cancer globally. In 2023, as reported by the American Cancer Society in their Ovarian Cancer Statistics, an estimated 19,710 new cases of cancer and 13,270 related deaths were anticipated in the USA alone. This rise in ovarian cancer incidence worldwide contributes significantly to the expansion of the ovarian cancer drugs market.

Government initiatives and funding for ovarian cancer are expected to significantly drive the growth of the ovarian cancer drugs market in the future. These initiatives provide financial support to selected entities with projects aimed at enhancing public services and the economy. Government aid in ovarian cancer research plays a crucial role in improving the quality of life and survival rates for patients with this disease. For example, in July 2022, the Ovarian Cancer Research Alliance, Inc., a US-based nonprofit organization, announced an additional allocation of $2 million for both Johanna's Law and the Ovarian Cancer Control Initiative, representing a substantial increase from the $500,000 increments approved for FY22. As a result, government initiatives and funding for ovarian cancer are driving growth in the ovarian cancer drugs market.

Major companies in the ovarian cancer drug market are concentrating on developing innovative solutions, such as treatments for breast and ovarian cancer, to enhance therapeutic efficacy and improve patient outcomes. Treatments for breast and ovarian cancer encompass various medical approaches aimed at managing and combating these distinct types of malignancies that affect women. For example, in June 2024, Shorla Oncology, an Ireland-based pharmaceutical company, received FDA approval for Tepylute, a new ready-to-dilute formulation of thiotepa designed for the treatment of breast and ovarian cancers. This liquid formulation simplifies administration by removing the need for complex reconstitution, ensuring consistent dosing accuracy. The recommended dosage ranges from 0.3 mg/kg to 0.4 mg/kg, administered intravenously every 1 to 4 weeks, beginning with higher initial doses followed by maintenance adjustments based on blood counts.

Major players in the ovarian cancer drug market are strategically focusing on producing innovative drugs, including antibody-drug conjugates, to drive market revenues. Antibody-drug conjugates (ADCs) represent a biopharmaceutical drug category that combines a monoclonal antibody (mAb) with a cytotoxic drug through a chemical linker. For instance, in November 2022, the US-based biotechnology company ImmunoGen, Inc. introduced Mirvetuximab soravtansine-gynx. This drug targets the overexpressed FRa protein on the surface of many cancer cells, including ovarian cancer cells. The antibody delivers the microtubule inhibitor soravtansine to the cancer cells, disrupting their mitosis and causing cell death. This ADC shows promise as a new treatment for patients with folate receptor alpha-positive, platinum-resistant ovarian cancer. It represents the first ADC approved for this type of cancer and has demonstrated positive outcomes in clinical trials.

In February 2024, AbbVie, an American pharmaceutical company, acquired ImmunoGen for $10.1 billion. This acquisition is intended to substantially enhance AbbVie's oncology portfolio by incorporating ImmunoGen's flagship therapy, ELAHERE, an antibody-drug conjugate approved for the treatment of platinum-resistant ovarian cancer. ImmunoGen is a U.S.-based biotechnology company that focuses on developing antibody-drug conjugates (ADCs) specifically for ovarian cancer treatment.

Major companies operating in the ovarian cancer drugs market include AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Amgen Inc, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer, Inc., Novartis AG, Pharma Mar SA, Vivesto, BDR Pharmaceutical, GLS Pharma, Eisai Co., Ltd., Denovo Biopharma, Jiangsu Hengrui Medicine, BeiGene, Innovent Biologics, Zai Lab, EUSA Pharma, Recordati, NEUCA, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, TZMO, Msd Sanofi, Gilead Sciences, Johnson & Johnson, Merck & Co, AbbVie Inc, Aa Pharma In, Aaladin Superior Cleaning Systems Ltd, Accel Pharma Inc, EMS Pharma, Eurofarma, Neo Quimica, Mantecorp Farmasa, Abbott Laboratories Bayer, Laboratorio Elea Phoenix, Laboratorios Ac Farma, Teva, Monte Verde, Gador, Spimaco, Tabuk Pharmaceuticals, Jamjoom Pharma, Abcon International L.L.C., Adcan Pharma, Regal Pharmaceuticals Limited

North America was the largest region in the ovarian cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global ovarian cancer drugs market share during the forecast period. The regions covered in the ovarian cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the ovarian cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The ovarian cancer drugs market consists of sales of Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, and Platinol (Cisplatin). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ovarian Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ovarian cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ovarian cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ovarian cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Tumor Type: Epithelial Ovarian Cancer, Germ Cell Ovarian Cancer, Stromal Cell Ovarian Cancer
• 2) By Drug Type: Alkylating Agents, Mitotic Inhibitors, VEGF/VEGFR inhibitors, PARP inhibitors, Other Drug Types
• 3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Other Distribution Channels
• Subsegments:
• 1) By Epithelial Ovarian Cancer: Serous Carcinoma; Endometrioid Carcinoma; Clear Cell Carcinoma; Mucinous Carcinoma
• 2) By Germ Cell Ovarian Cancer: Dysgerminoma; Yolk Sac Tumor; Teratoma; Embryonal Carcinoma
• 3) By Stromal Cell Ovarian Cancer: Granulosa Cell Tumor; Sertoli-Leydig Cell Tumor; Thecoma; Fibroma
• Companies Mentioned: AstraZeneca plc; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Amgen Inc; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ovarian Cancer Drugs Market Characteristics

3. Ovarian Cancer Drugs Market Trends And Strategies

4. Ovarian Cancer Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Ovarian Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ovarian Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ovarian Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Ovarian Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ovarian Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ovarian Cancer Drugs Total Addressable Market (TAM)

6. Ovarian Cancer Drugs Market Segmentation

• 6.1. Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epithelial Ovarian Cancer
• Germ Cell Ovarian Cancer
• Stromal Cell Ovarian Cancer
• 6.2. Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alkylating Agents
• Mitotic Inhibitors
• VEGF/VEGFR inhibitors
• PARP inhibitors
• Other Drug Types
• 6.3. Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Stores
• Other Distribution Channels
• 6.4. Global Ovarian Cancer Drugs Market, Sub-Segmentation Of Epithelial Ovarian Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serous Carcinoma
• Endometrioid Carcinoma
• Clear Cell Carcinoma
• Mucinous Carcinoma
• 6.5. Global Ovarian Cancer Drugs Market, Sub-Segmentation Of Germ Cell Ovarian Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dysgerminoma
• Yolk Sac Tumor
• Teratoma
• Embryonal Carcinoma
• 6.6. Global Ovarian Cancer Drugs Market, Sub-Segmentation Of Stromal Cell Ovarian Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulosa Cell Tumor
• Sertoli-Leydig Cell Tumor
• Thecoma
• Fibroma

7. Ovarian Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ovarian Cancer Drugs Market

• 8.1. Asia-Pacific Ovarian Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ovarian Cancer Drugs Market

• 9.1. China Ovarian Cancer Drugs Market Overview
• 9.2. China Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ovarian Cancer Drugs Market

• 10.1. India Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ovarian Cancer Drugs Market

• 11.1. Japan Ovarian Cancer Drugs Market Overview
• 11.2. Japan Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ovarian Cancer Drugs Market

• 12.1. Australia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ovarian Cancer Drugs Market

• 13.1. Indonesia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ovarian Cancer Drugs Market

• 14.1. South Korea Ovarian Cancer Drugs Market Overview
• 14.2. South Korea Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ovarian Cancer Drugs Market

• 15.1. Western Europe Ovarian Cancer Drugs Market Overview
• 15.2. Western Europe Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ovarian Cancer Drugs Market

• 16.1. UK Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ovarian Cancer Drugs Market

• 17.1. Germany Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ovarian Cancer Drugs Market

• 18.1. France Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ovarian Cancer Drugs Market

• 19.1. Italy Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ovarian Cancer Drugs Market

• 20.1. Spain Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ovarian Cancer Drugs Market

• 21.1. Eastern Europe Ovarian Cancer Drugs Market Overview
• 21.2. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ovarian Cancer Drugs Market

• 22.1. Russia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ovarian Cancer Drugs Market

• 23.1. North America Ovarian Cancer Drugs Market Overview
• 23.2. North America Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ovarian Cancer Drugs Market

• 24.1. USA Ovarian Cancer Drugs Market Overview
• 24.2. USA Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ovarian Cancer Drugs Market

• 25.1. Canada Ovarian Cancer Drugs Market Overview
• 25.2. Canada Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ovarian Cancer Drugs Market

• 26.1. South America Ovarian Cancer Drugs Market Overview
• 26.2. South America Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ovarian Cancer Drugs Market

• 27.1. Brazil Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ovarian Cancer Drugs Market

• 28.1. Middle East Ovarian Cancer Drugs Market Overview
• 28.2. Middle East Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ovarian Cancer Drugs Market

• 29.1. Africa Ovarian Cancer Drugs Market Overview
• 29.2. Africa Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ovarian Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Ovarian Cancer Drugs Market Competitive Landscape
• 30.2. Ovarian Cancer Drugs Market Company Profiles
  • 30.2.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Ovarian Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Clovis Oncology
• 31.2. Pfizer, Inc.
• 31.3. Novartis AG
• 31.4. Pharma Mar SA
• 31.5. Vivesto
• 31.6. BDR Pharmaceutical
• 31.7. GLS Pharma
• 31.8. Eisai Co., Ltd.
• 31.9. Denovo Biopharma
• 31.10. Jiangsu Hengrui Medicine
• 31.11. BeiGene
• 31.12. Innovent Biologics
• 31.13. Zai Lab
• 31.14. EUSA Pharma
• 31.15. Recordati

32. Global Ovarian Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ovarian Cancer Drugs Market

34. Recent Developments In The Ovarian Cancer Drugs Market

35. Ovarian Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Ovarian Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ovarian Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ovarian Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer